Company Filing History:
Years Active: 2013
Title: Jack Puymirat: Innovator in Prostaglandin E2 Modulation
Introduction
Jack Puymirat is a notable inventor based in California, recognized for his contributions to medical science. He has developed innovative methods for the prognosis, diagnosis, prevention, and treatment of myotonic dystrophy type 1 (DM1). His work focuses particularly on the congenital form of this condition, known as congenital myotonic dystrophy type 1 (cDM1).
Latest Patents
Jack Puymirat holds 1 patent for his invention titled "Prostaglandin E2 modulation and uses thereof." This patent describes various methods, uses, kits, and products that leverage changes in or modulation of prostaglandin E (PGE) to address DM1.
Career Highlights
Jack Puymirat is affiliated with Université Laval, where he continues to advance research in his field. His work has significant implications for improving the quality of life for individuals affected by myotonic dystrophy.
Collaborations
Jack has collaborated with esteemed colleagues, including Daniel Beaulieu and Pierre Chapdelaine, to further enhance the impact of his research.
Conclusion
Jack Puymirat's innovative work in prostaglandin E2 modulation represents a significant advancement in the treatment of myotonic dystrophy type 1. His contributions are paving the way for new therapeutic approaches in this challenging medical field.